An Official Website of the United States Government
Company Information:
Name:
EUTROPICS PHARMACEUTICALS, INC.
Address:
60 GRAMPIAM WAY
DORCHESTER, MA 02125-
DORCHESTER, MA 02125-
Located in HUBZone:
No
Woman-Owned:
No
Minority-Owned:
No
URL:
N/A
Phone:
N/A
Award Totals:
Award List:
Development of small molecule inhibitors of Mcl-1 for cancer treament
Award Year / Program / Phase:
2008 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Award Amount:
$326,983.00
Abstract:
DESCRIPTION (provided by applicant): The Bcl-2 family proteins are key effectors of cancers. Recent studies indicate that Myeloma cell factor-1(Mcl-1), a member of this protein family, is a key regulator of lymphoid cancers including B-cell lymphoma, mul
tiple myeloma, and chronic lymphocytic… More
BH3 Profiling as a Companion Diagnostic For Velcade
Award Year / Program / Phase:
2010 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Michael Cardone – (617) 314-6431
Award Amount:
$199,860.00
Abstract:
There is a clear need to better define patient-specific treatment strategies for the use of both standard and novel therapies for treating multiple myeloma. Eutropics is uniquely positioned to improve therapy efficacy for multiple myeloma by using a proprietary assay that provides a novel predictive… More
Development of small molecule inhibitor of Mcl-1 for cancer treatment
Award Year / Program / Phase:
2010 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Michael H. Cardone
Award Amount:
$1,357,725.00
Abstract:
DESCRIPTION (provided by applicant): The Bcl-2 family proteins are key effectors of cancers. Recent studies indicate that Myeloma cell factor-1 (Mcl-1), a member of this protein family, is a key regulator of lymphoid cancers including Multiple Myeloma (MM)
, Non-Hodgkin's Lymphoma (NHL), and other… More
IGF::OT::IGF OTHER FUNCTIONS TOPIC 277, DEVELOPING BH3 PROFILING AS A COMPANION DIAGNOSTIC FOR VELCADE TREATMENT FOR MULTIPLE MYELOMA
Award Year / Program / Phase:
2012 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Michael Cardone – 617-714-4405
Award Amount:
$1,499,746.00
Abstract:
There is a clear need to better define patient-specific treatment strategies for the use of both standard and novel therapies for treating Multiple Myeloma (MM) both to improve efficacy and reduce unnecessary side effects. Eutropics Pharmaceuticals is uniquely positioned to improve therapy efficacy… More
IGF::OT::IGF OTHER FUNCTIONS RandD- BIOMEDICAL (BASIC RESEARCH)
Award Year / Program / Phase:
2012 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Michael Cardone – 617-714-4405
Award Amount:
$199,892.00
Abstract:
There is a clear need to better define patient-specific treatment strategies for the use of both standard and novel therapies for treating Acute Myelogenous Leukemia (AML) both to improve efficacy and reduce unnecessary side effects. Eutropics Pharmaceuticals is uniquely positioned to improve… More